moxifloxacin has been researched along with Impotence, Arteriogenic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, P; Borer, J | 1 |
1 other study(ies) available for moxifloxacin and Impotence, Arteriogenic
| Article | Year |
|---|---|
Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adolescent; Adult; Advisory Committees; Anti-Infective Agents; Aza Compounds; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Dose-Response Relationship, Drug; Drug Approval; Electrocardiography; Fluoroquinolones; Humans; Imidazoles; Impotence, Vasculogenic; Male; Middle Aged; Moxifloxacin; Phosphoric Diester Hydrolases; Piperazines; Prostatic Hyperplasia; Quinazolines; Quinolines; Risk Assessment; Sulfones; Triazines; United States; United States Food and Drug Administration; Vardenafil Dihydrochloride | 2003 |